Director, Chief Executive Officer · Estrella Immunopharma, Inc. · Estrella Immunopharma, Inc. — Stock Option (Right to Buy)
Side
A
Value
—
Shares
1.00M
Price
—
Executed
Nov 2, 2026
Disclosed
Nov 4, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Nov 2 executedNov 4, 2026 disclosed
ESLA · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Estrella Immunopharma, Inc. — Stock Option (Right to Buy)
Ticker
ESLA
Shares
1.00M
Price per share
$0
Execution date (reported)
Nov 2, 2026
Owned after transaction
1.00M shares
Days from execution to publication
2
What this establishes
Pussinen Cynthia filed this Form 4 reporting a grant or award of ESLA on Nov 2, 2026. It became public on Nov 4, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director, Chief Executive Officer
Pussinen Cynthiacik:0002163153
Issuer
Estrella Immunopharma, Inc.cik:0001844417
Revision history · 0
No field has changed since this record was first ingested.
